| UNIVERSITY OF KENTUCKY Patent applications |
| Patent application number | Title | Published |
|---|
| 20110166208 | Nucleotide and Amino Acid Sequences for Calmodulin Protein Methyltransferase - The present invention provides nucleic acid and amino acid sequences for calmodulin protein methyltransferase. The present invention also provides diagnostic tools and methods of using the present invention to diagnose and treat diseases and conditions linked with calmodulin methyltransferase, as well as methylated calmodulin intermediates. | 07-07-2011 |
| 20100184745 | USE OF PARTHENOLIDE DERIVATIVES AS ANTILEUKEMIC AND CYTOTOXIC AGENTS - The present invention provides compounds of the formula (I) | 07-22-2010 |
| 20090247619 | Cannabinoid-Containing Compositions and Methods for Their Use - This invention relates to cannabinoid-containing compositions, particularly cannabinoid-containing gel formulations and methods for the treatment of traumatic injury, e.g., strains, sprains and contusions, and disease conditions, e.g., arthritis, particularly osteoarthritis. The methods involve topically applying a cannabinoid or a cannabinoid-containing composition to a subject's skin near, or distant from, the area of the injury or the area affected by the disease condition, e.g., an arthritic joint. The cannabinoid-containing composition is preferably a pharmaceutically acceptable gel containing a therapeutically effective amount of a cannabinoid sufficient to alleviate the symptoms associate with the injury or disease condition. | 10-01-2009 |
| 20090197285 | Lung Cancer Diagnostic Assay - A diagnostic assay for determining presence of lung cancer in a patient depends, in part, on ascertaining the presence of an antibody associated with lung cancer. The assay predicted lung cancer prior to evidence of radiographically detectable cancer tissue. | 08-06-2009 |
| 20090186376 | sVEGFR-2 AND ITS ROLE IN LYMPHANGIOGENESIS MODULATION - Disclosed herein are nucleic acid molecules comprising a nucleotide sequence of sVEGF-2, proteins encoded by those sequences and antibodies that bind to the protein. Also disclosed are methods for inhibiting or enhancing expression or activity of sVEGFR-2 and methods for inhibiting graft rejection, particularly cornea graph rejection. Also described are methods for inhibiting lymphangiogenesis and lymphatic endothelial cell proliferation by administering an effective amount of sVEGFR-2 and methods for treating lymphedema by inhibiting the activity of sVEGFR-2. | 07-23-2009 |
